Close Menu

Margot Schoenborn

Jun 26, 2019

OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO. Schoenborn joined the firm as senior VP, general counsel and corporate secretary in 2015 and was later appointed chief administrative officer. Prior to OmniSeq, Schoenborn served as deputy general counsel at the Roswell Park Comprehensive Cancer Center. Before that, she served as a special assistant attorney general for New York and as a assistant US attorney for the Eastern District of New York. 

More Like This

Sep 19, 2019

Cergentis: Jan Groen, Wim Van Criekinge, Maaike Van Min

The Netherlands-based genomics company Cergentis has appointed Jan Groen, Wim Van Criekinge, and Maaike Van Min to its board of directors. Groen currently serves as CEO of Novigenix. Wim has over 20 years of experience in the life sciences industry as a strategic, scientific consultant and business executive in diagnostic and biotech companies. 

Sep 19, 2019

Sophia Genetics: Gaëtan Fraikin, Sergei Yakneen

Sophia Genetics has hired Gaëtan Fraikin as chief marketing officer and Sergei Yakneen as chief information officer. Fraikin joins the Swiss company after short stints with Addictive, Roche, and Illumina, plus 14 years as a marketing agency executive. Yakneen is a former technical officer with the European Molecular Biology Laboratory and led the technical working group of the Pan Cancer Analysis of Whole Genomes project for the Ontario Institute for Cancer Research. 

Sep 18, 2019

Fred Hutchinson Cancer Research Center: Gary Gilliland

The Fred Hutchinson Cancer Research Center announced that D. Gary Gilliland plans to step down as president and director in 2020. Prior to working at the Hutch, Gilliland served as director of the leukemia program at Dana-Farber/Harvard Cancer, senior VP and global oncology franchise head at Merck, and vice dean and VP of precision medicine at Perelman School of Medicine at the University of Pennsylvania. 

Sep 17, 2019

Pressure BioScience: Daniel Shea

Pressure BioSciences has appointed Daniel Shea as senior VP and CFO, effective Friday Sept. 13. Prior to Pressure BioSciences, Shea has operated Woodcliff Advisors since Jan. 2017. From 1998 to 2016, Shea served as senior VP at Affiliated Managers Group. Prior to that, he advised financial services firms at PricewaterCoopers.

Sep 17, 2019

Ontera: Mark Rose and Raparti Swayambhu

Nanopore diagnostics firm Ontera has appointed Mark Rose as VP of product management and Raparti Swayambhu as VP of software.

Rose will be responsible for development, launch, and commercial activities of the firm's diagnostic product portfolio. He comes from Google, where he was a product lead and helped launch the Nest brand of internet-connected devices for the home. He has also worked at Motorola and Facebook. He holds an MBA from the Craig School of Business at California State University, Fresno.

Swayambhu will oversee the firm's software development, enterprise IT, and data science teams. He brings more than 20 years of experience in software development and has held technical leadership roles at Sema4 and Genentech, among other firms. He holds a master's degree in computer science from Carnegie Mellon University.

Sep 16, 2019

DermTech: Kevin Sun, Steven Kemper

DermTech has appointed Kevin Sun as CFO, treasurer, and secretary. He will be replacing CFO Steven Kemper, who will be retiring in October. Prior to DermTech, Sun served in various executive and management roles at DexCom, most recently as VP, corporate controller and treasury, interim CFO, and VP, Finance. Before DexCom, Sun held various roles at Biosite. 

Sep 13, 2019

Personalis: Karin Eastham

Menlo Park, California-based Personalis has appointed Karin Eastham as independent director to its board of directors. Eastham currently serves as board member for Geron, Veracyte, and Nektar Therapeutics. Prior to Personalis, Eastham served as executive VP and chief operating officer, as well as a member of the board of trustees, at the Burnham Institute for Medical Research from 2004 to her retirement in 2008. She previously served on the boards of Illumina, MorphoSys, Trius Therapeutics, Amylin Pharmacueticals, Genoptix, Tercica, and SGX Pharmaceuticals. 

Sep 13, 2019

QuantuMDx: Neil Butler

UK-based QuantuMDx has appointed Neil Butler as its non-executive director. Butler currently serves on the board of Nidor Dx, Radisens, and Spectromics. He previously served as chair and non-executive director for Atlast Genetics/Binx Health and Genomic Vision. 

Sep 12, 2019

Biocrates: Nicolas Schauer, Moritz Seuster, Wulf Fischer-Knuppertz

Austria-based Biocrates announced that it has appointed Nicolas Schauer as co-CEO and CSO along with Moritz Seuster as co-CEO and CFO. Wulf Fischer-Knuppertz is resigning from the firm's executive board and will continue to serve as a consultant. Prior to joining Biocrates, Schauer sold his own metabolite profiling company in 2017. 

Sep 12, 2019

ACMG Foundation: Brynn Levy, David Tilstra

Brynn Levy and David Tilstra have been elected to the board of directors of the ACMG Foundation for Genetic and Genomic Medicine, a nonprofit organization that facilitates the integration of genetics and genomics into medical practice.

Levy is a professor in the Department of Pathology & Cell Biology at Columbia University Irving Medical Center and co-director of the department's division of personalized genomic medicine. In addition, he is the medical director of the clinical cytogenetics laboratory of New York Presbyterian Hospital.

Tilstra is president emeritus of CentraCare Clinic. Until the end of 2018, he was the clinic's president, and before that, its medical director. Tilstra holds an MBA from the University of Colorado Denver, an MD from the University of Iowa College of Medicine, and an undergraduate degree in chemistry from Northwestern College of Orange City.

Sep 11, 2019

PharmGKB: Michelle Whirl-Carrillo

Michelle Whirl-Carrillo has been named director of PharmGKB. Since 2014, she has been associate director of the organization, and before that, she was assistant director and lead curator. Whirl-Carrillo holds a PhD in biophysics from Stanford University and an undergraduate degree in biology from MIT.

Sep 11, 2019

Waters: Mark Beaudouin, Keely Aleman

Waters has announced that Mark Beaudouin is retiring as senior VP, general counsel, and corporate secretary. Keeley Aleman, who is the firm's current VP, deputy general counsel and assistant secretary, will take his place. Prior to joining Waters in 2006, Aleman held corporate associate positions at Goodwin Proctor and Testa, Hurwitz & Thibeault. 

Sep 11, 2019

Syapse: Fletcher Payne

Fletcher Payne has been appointed as CFO of precision oncology firm Syapse. Payne joins Syapse from Catalyst Biosciences, where he was CFO since January 2015. He has previously held senior financial positions at CytomX Therapeutics, Plexxikon, Rinat Neuroscience Corporation, Dynavax Technologies Corporation, Cell Genesys, Abgenix, Sun Microsystems, and IBM. 

Sep 10, 2019

Epic Sciences: Joel Smith

San Diego-based Epic Sciences has appointed Joel Smith as its general counsel and executive VP of corporate development. Prior to Epic Sciences, Smith acted as managing counsel of Qualcomm Life. Smith has also served as senior executive and general counsel at biotech and life science companies including BioQ, Triad Therapeutics, and Sientra.


Sep 10, 2019

Quest Diagnostics: Manuel Méndez

Quest Diagnostics has named Manuel Méndez its senior VP and chief commercial officer, effective Oct. 7. Méndez is leaving Qiagen, where he currently is senior VP, global commercial operations and a member of the executive committee. Prior to joining Qiagen, he was executive VP Americas for BioMérieux.

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.